Holds one active US DMF for olaparib, filing since 2021. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 23 markets.
Holds one active US DMF for olaparib, filing since 2021. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 23 markets.
Holds one active US DMF for olaparib, filing since 2021. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 26 markets.
Holds one active US DMF for olaparib, filing since 2018. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 18 markets.
Holds one active US DMF for olaparib, filing since 2025. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 29 markets.
Holds 2 active US DMFs for olaparib, filing since 2020. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 26 markets.
Holds one active US DMF for olaparib, filing since 2026. Its GMP is recognised in 12 markets.
Holds one active US DMF for olaparib, filing since 2022. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 34 markets.
Holds 2 active US DMFs for olaparib, filing since 2023. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 1 market.
Holds 2 active US DMFs for olaparib, filing since 2018. Its 2022 FDA inspection closed as NAI, and its GMP is recognised in 1 market.
Holds 2 active US DMFs for olaparib, filing since 2024. Its 2024 FDA inspection closed as NAI, and its GMP is recognised in 2 markets.
Holds one active US DMF for olaparib, filing since 2024. Its GMP is recognised in 3 markets.
Holds one active US DMF for olaparib, filing since 2023. Its 2024 FDA inspection closed as NAI.
Holds 2 active US DMFs for olaparib, filing since 2024. Its 2022 FDA inspection closed as NAI, and its GMP is recognised in 1 market.
Holds one active US DMF for olaparib, filing since 2023. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 3 markets.
Holds one active US DMF for olaparib, filing since 2023. Its 2019 FDA inspection closed as VAI, and its GMP is recognised in 1 market.
Holds one active US DMF for olaparib, filing since 2025. Its GMP is recognised in 1 market.
Holds one active US DMF for olaparib, filing since 2016.
Holds 2 active US DMFs for olaparib, filing since 2024.
Registered with SFDA (Saudi Arabia) for olaparib. Its 2022 FDA inspection closed as VAI.
The names are listed below. Ask Fred about the filings, inspection history and GMP certificates on record for each manufacturer.
The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Every factor appears on the card it produced. Read the full method.
Ask Fred which manufacturers are on record for olaparib and what filings they hold.
Chat with Fred, your AI analyst